Conditions: Neovascular Age-related Macular Degeneration
Keywords: wet age-related macular degeneration (AMD) ranibizumab aflibercept Best Corrected Visual Acuity (BCVA) Spectral Domain Optical Coherence Tomography (SD-OCT)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 712
Healthy volunteers: no

Brief summary:
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.

Detailed description:
Patients attended 14 scheduled study visits during 12 months.

Arms:
arm 1: 1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity arm 2: 1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months

Interventions: intervention 1: Ranibizumab intervention 2: Aflibercept
Intervention descriptions: intervention 1: 0.5 mg intravitreal injection intervention 2: 2 mg intravitreal injection

Protocol document: